NCT03769415 Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
| NCT ID | NCT03769415 |
| Status | Recruiting |
| Phase | — |
| Sponsor | UNC Lineberger Comprehensive Cancer Center |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2018-11-06 |
| Primary Completion | 2030-12-15 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The HARMONY trial is an interventional trial enrolling metastatic breast cancer (MBC). Current treatment of breast cancer uses clinical subtype information (e.g. hormone receptor-positive (HR+)) to help guide treatment options. Breast cancer can also be characterized by molecular subtype, but it is not known if this information is helpful in determining treatment when breast cancer has become metastatic. HARMONY will give the treating physician of each participant the molecular subtype of the tumor based on PAM50 testing. The usefulness of this information will be determined through the physician survey. Finding out the molecular subtype of each tumor also allows the investigators to determine if the molecular subtype is different from what is expected based on the clinical subtype. This study will help determine how new types of information about tumors can help choose treatments for MBC
Eligibility Criteria
Inclusion Criteria: * Women or men at least 18 years of age * Pathologically documented diagnosis of measurable or evaluable metastatic breast cancer with known ER, PR, and HER2 status determined by the local laboratory on the primary tumor. * Enrolled before or during first line of treatment for metastatic breast cancer. No more than 1 prior line of therapy in the metastatic setting. * Accessible medical records for all treatment and response data in the metastatic setting. * Willing and able to receive medical treatment or follow up by investigators at UNC-Chapel Hill. * Receiving treatment for metastatic breast cancer. * Treating physician considers patient well enough for standard of care therapy including chemotherapy. * Willing to give blood for research purposes upon study enrollment and at first disease progression. * Available archival primary tumor suitable for molecular analysis. If the primary is not available, willingness to obtain extra samples for research during planned
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.